Catherine A. Shu

4.1k total citations · 1 hit paper
64 papers, 1.5k citations indexed

About

Catherine A. Shu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Catherine A. Shu has authored 64 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 45 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Catherine A. Shu's work include Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Catherine A. Shu is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Catherine A. Shu collaborates with scholars based in United States, South Korea and France. Catherine A. Shu's co-authors include Naiyer A. Rizvi, Anjali Saqi, Joshua Sonett, Mark Stoopler, Simon K. Cheng, Claud Grigg, Mark M. Awad, Justin F. Gainor, Codruța Chiuzan and F. D’Ovidio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Catherine A. Shu

57 papers receiving 1.5k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 425 citations Catherine A. Shu, Justin F. Gainor et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine A. Shu United States	19	1.0k	1.0k	265	190	161	64	1.5k
Satoru Kitazono Japan	23	1.0k 1.0×	833 0.8×	349 1.3×	252 1.3×	108 0.7×	92	1.5k
Xiaoyu Tu China	13	688 0.7×	567 0.6×	520 2.0×	305 1.6×	56 0.3×	39	1.5k
Tiffany G. Huynh United States	12	765 0.7×	574 0.6×	380 1.4×	215 1.1×	103 0.6×	21	1.2k
Sara Cresta Italy	20	597 0.6×	461 0.5×	422 1.6×	193 1.0×	142 0.9×	55	1.3k
Jorge Chaves United States	16	909 0.9×	365 0.4×	211 0.8×	147 0.8×	283 1.8×	41	1.2k
Jari Sundström Finland	22	520 0.5×	295 0.3×	484 1.8×	332 1.7×	154 1.0×	49	1.2k
Francesca Negri Italy	21	1.0k 1.0×	422 0.4×	394 1.5×	285 1.5×	273 1.7×	61	1.7k
Mateus Crespo United Kingdom	17	421 0.4×	525 0.5×	399 1.5×	393 2.1×	61 0.4×	44	1.0k
Haruhiro Saito Japan	23	975 0.9×	1.3k 1.3×	364 1.4×	236 1.2×	120 0.7×	142	1.9k
Zhanhong Xie China	18	761 0.7×	519 0.5×	227 0.9×	172 0.9×	164 1.0×	60	1.1k

Countries citing papers authored by Catherine A. Shu

Since Specialization

Citations

This map shows the geographic impact of Catherine A. Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine A. Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine A. Shu more than expected).

Fields of papers citing papers by Catherine A. Shu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine A. Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine A. Shu. The network helps show where Catherine A. Shu may publish in the future.

Co-authorship network of co-authors of Catherine A. Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine A. Shu. A scholar is included among the top collaborators of Catherine A. Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine A. Shu. Catherine A. Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jurkiewicz, Magdalena, Raymond Yeh, Catherine A. Shu, et al.. (2025). Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers. SHILAP Revista de lepidopterología. 6(1). 5–5.

May, Michael, Jonathan Lee, Xin Ma, et al.. (2025). The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer. JNCI Journal of the National Cancer Institute. 118(1). 49–57.

Keating, Claire, et al.. (2024). Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer. Respiratory Medicine Case Reports. 51. 102091–102091.

Henick, Brian S., Peter D. Koch, Justin F. Gainor, et al.. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer. 12(12). e009301–e009301. 4 indexed citations

Craig, Jesse C., et al.. (2024). AB0250 A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP CLINICAL TRIAL OF NIPOCALIMAB IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (SPIREA): STUDY DESIGN. Annals of the Rheumatic Diseases. 83. 1365–1365.

Jin, Weimin, Huijuan Yang, Zegeng Li, et al.. (2024). Inhalable cyclodextrin metal-organic framework dry powder enhanced direct pulmonary delivery of paclitaxel for the treatment of lung cancer. Journal of Drug Delivery Science and Technology. 101. 106310–106310. 4 indexed citations

Ma, Xin, et al.. (2024). Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer. The Oncologist. 30(8). 1 indexed citations

Henick, Brian S., et al.. (2023). Severe scalp ulcerations and granulomata during treatment with amivantamab. SHILAP Revista de lepidopterología. 13. 100273–100273. 2 indexed citations

Kidane, Biniam, Matthew J. Bott, Jonathan Spicer, et al.. (2023). The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 166(3). 637–654. 24 indexed citations

10.

Piotrowska, Zofia, Elaine Shum, Ying Liu, et al.. (2023). Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.. Journal of Clinical Oncology. 41(16_suppl). 9108–9108. 4 indexed citations

11.

Le, Xiuning, Elaine Shum, Christina S. Baik, et al.. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology. 34. S1313–S1314. 8 indexed citations

12.

Wei, Alexander Z., et al.. (2023). Neoadjuvant immunotherapy in resectable non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 15. 2608534–2608534. 14 indexed citations

13.

Washburn, Robert S., Radomir Kratchmarov, Shana M. Coley, et al.. (2022). Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy. Cancer Immunology Research. 11(2). 164–170. 13 indexed citations

14.

Park, Keunchil, Joshua K. Sabari, Eric B. Haura, et al.. (2022). MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study. Annals of Oncology. 33. S482–S482. 1 indexed citations

15.

Ramalingam, Suresh S., Marwan Fakih, John H. Strickler, et al.. (2021). Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors. Molecular Cancer Therapeutics. 20(12_Supplement). P05–1. 28 indexed citations

16.

May, Michael, Connor J. Kinslow, Christopher Adams, et al.. (2021). Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States. Translational Lung Cancer Research. 10(1). 71–79. 15 indexed citations

17.

Feldman, Jarett L., et al.. (2020). Hepatoid Adenocarcinoma of the Lung Responsive to Frontline Combination Chemotherapy With Immunotherapy: Case Report. JTO Clinical and Research Reports. 2(2). 100130–100130. 4 indexed citations

18.

Sung, Simon, Jonas J. Heymann, John P. Crapanzano, et al.. (2020). Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. Journal of the American Society of Cytopathology. 9(5). 332–345. 25 indexed citations

19.

Bender, David A, et al.. (2020). Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease. Journal for ImmunoTherapy of Cancer. 8(2). e001627–e001627. 11 indexed citations

20.

Heymann, Jonas J., William A. Bulman, David Swinarski, et al.. (2017). PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathology. 125(12). 896–907. 158 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact